Two advancements in eosinophilic esophagitis — the success of the biologic therapy Dupixent in reducing symptoms and improving quality-of life, and the accuracy of a minimally invasive diagnostic test in distinguishing active vs. inactive disease — were among the stop stories in gastroenterology last week.
Another top story: Findings suggest the reason some patients with inflammatory bowel disease do not respond anti-TNF therapy could be explained by a genetic variant carried by 40% of Europeans.
This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.